Mallolas J - Search Results

1

Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.

Navarrete P, Morente V, García F, Alós L, Arnedo M, Plana M, Gil C, Caballero M, Miró JM, Martínez E, Fumero E, Castro P, Blanco JL, Mallolas J, Blanch JL, Cruceta A, Mestre G, Pumarola T, Gallart T, Gatell JM. Navarrete P, et al. Among authors: mallolas j. Antivir Ther. 2003 Dec;8(6):635-7. Antivir Ther. 2003. PMID: 14760898

2

Serum levels of beta2-microglobulin, neopterin, TNF-alpha and soluble receptors of TNF-alpha and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection.

Bedini JL, García F, Miró JM, Aznar E, Serrano J, Lozano L, Mallolas J, Filella X, Vidal J, Latorre X, Gatell JM, Ballesta AM, Soriano E. Bedini JL, et al. Among authors: mallolas j. Clin Microbiol Infect. 1998 Jan;4(1):4-10. doi: 10.1111/j.1469-0691.1998.tb00327.x. Clin Microbiol Infect. 1998. PMID: 11864226 Free article.

3

[Comparison of three methods to calculate adherence in patients receiving antiretroviral treatment].

Codina C, Martínez M, Tuset M, del Cacho E, Martín MT, Miró JM, Mallolas J, de Lazzari E, García F, Martínez E, Gatell JM, Ribas J. Codina C, et al. Among authors: mallolas j. Enferm Infecc Microbiol Clin. 2002 Dec;20(10):484-90. doi: 10.1016/s0213-005x(02)72850-4. Enferm Infecc Microbiol Clin. 2002. PMID: 12433349 Spanish.

4

Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis.

Garcia F, Plana M, Mestre G, Cruceta A, Martinez E, Miró JM, Mallolas J, Tuset M, Pumorola T, Gallart T, Gatell JM. Garcia F, et al. Among authors: mallolas j. Antivir Ther. 2002 Sep;7(3):195-7. Antivir Ther. 2002. PMID: 12487387 Clinical Trial.

5

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM; BEST Study Team. Arnaiz JA, et al. Among authors: mallolas j. AIDS. 2003 Apr 11;17(6):831-40. doi: 10.1097/00002030-200304110-00008. AIDS. 2003. PMID: 12660530 Clinical Trial.

6

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J. Walker UA, et al. Among authors: mallolas j. Hepatology. 2004 Feb;39(2):311-7. doi: 10.1002/hep.20074. Hepatology. 2004. PMID: 14767983

7

Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].

Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Berenguer J, et al. Among authors: mallolas j. Enferm Infecc Microbiol Clin. 2004 Mar;22(3):160-76. doi: 10.1016/s0213-005x(04)73057-8. Enferm Infecc Microbiol Clin. 2004. PMID: 14987537 Review. English, Spanish.

8

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: mallolas j. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13. doi: 10.1097/00126334-200406010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15167289

9

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

Martínez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, Mallolas J, García F, Miró JM, Gatell JM. Martínez E, et al. Among authors: mallolas j. Lancet. 2004 Jul 3-9;364(9428):65-7. doi: 10.1016/S0140-6736(04)16591-4. Lancet. 2004. PMID: 15234858

10

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Laguno M, et al. Among authors: mallolas j. AIDS. 2004 Sep 3;18(13):F27-36. doi: 10.1097/00002030-200409030-00003. AIDS. 2004. PMID: 15316335 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters